Evaluation of White Sweet Potato Tube Feeding Formula on Type 2 Diabetic Residents in Long-term Care Institutions

April 9, 2019 updated by: Taipei Medical University

Office of Human Research, Taipei Medical University

In order to response the increasing of aging population cause losing ability that need long-care needs, the project entitled "10-year long-term care program" from Executive Yuan in 2007 is carried out to assist economically disadvantaged and disabled elderly to acquire daily nutrition. Therefore, the long-term care resident's nutritional status got more attention than before. Out of control in blood glucose will not only increase bed sores and urinary tract infection in tube feeding residents but also rise medical expenditures. The nutritional status of long-term care institutions, anyang homes and nursing home are generally bad in nutrition management due to high cost of nutritional supplements from foreign imports that cause the burden of families. In this study, we will recruit diabetic subjects that divide into white sweet potato group (experimental group) and commercial formula group (control group) by using randomized, parallel and open clinical study through tube feeding in sixty days.

Study Overview

Detailed Description

All subjects will be evaluated the blood sugar and clinical nutrition assessment such as postural measurement, urine test and blood biomarker examination.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Long-term stability nasogastric or gastrostomy-fed person.
  • The physician diagnosed as diabetic and regular use of hypoglycemic drugs.

Exclusion Criteria:

  • Psychosis or depression.
  • Hba1c> 8.5%.
  • High taking nutritional supplements or steroids drugs.
  • Have undergone abdominal surgery caused by intestinal sticky.
  • Suffering from cancer, ulcers, respiratory infections and other diseases.
  • Currently receiving central venous nutrition therapy or intravenous nutrition therapy.
  • Liver dysfunction (ALT ≧ 100 U / L), renal insufficiency (creatinine ≧ 3mg / dl), heart failure (NYFc II above), moderate anemia (hemoglobin <9 g / dl).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control Group
Commercial diabetic formula
The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
Other Names:
  • diabetic formula
Experimental: Treatment Group
White sweet potato formula
The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
Other Names:
  • White sweet potato

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HbA1c After Intervention
Time Frame: 60 days
HbA1c value after 60 days intervention in both groups
60 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Albumin After Intervention
Time Frame: 60 days
Albumin value after 60 days intervention in both groups
60 days
Glucose After Intervention
Time Frame: 60 days
Glucose value after 60 days intervention in both groups
60 days
Total Cholesterol After Intervention
Time Frame: 60 days
Total cholesterol value after 60 days intervention in both groups
60 days
Triglyceride After Intervention
Time Frame: 60 days
Triglyceride value after 60 days intervention in both groups
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Actual)

November 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

November 17, 2015

First Submitted That Met QC Criteria

March 13, 2016

First Posted (Estimate)

March 17, 2016

Study Record Updates

Last Update Posted (Actual)

July 1, 2019

Last Update Submitted That Met QC Criteria

April 9, 2019

Last Verified

May 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • 201505027

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on Commercial diabetic formula

3
Subscribe